Tags:Varlilumab 代理商,Varlilumab 價(jià)格,Varlilumab 供應(yīng)商， Varlilumab supplier,Varlilumab purchase,Varlilumab 購(gòu)買(mǎi),Varlilumab 銷(xiāo)售

Description

Varlilumab is a fully human monoclonal antibody (mAb) that targets CD27, a critical molecule in the activation pathway of lymphocytes. Like CD40, CD27 can be effectively manipulated with activating antibodies to induce potent anti-tumor responses, and may result in less toxicities due to its restricted expression and regulation. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors.

Catalog No.

DHD72201

Host species

Homo sapiens

Species reactivity

Human

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

0.63 mg/ml

Purity

>95%

Clonality

Monoclonal

Isotype

IgG1-kappa

Applications

Research Grade Biosimilar

Target

CD27L receptor, TNFRSF7, T14, CD27 antigen, Tumor necrosis factor receptor superfamily member 7, CD27, T-cell activation antigen CD27

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

XtenCHO

Accession

P26842

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

1F5, CDX-1127, CAS: 1393344-72-3

Note

For research use only. Not suitable for clinical or therapeutic use.